Loading...
Pegvisomant in the treatment of acromegaly.
Parkinson, Craig Scarlett, J A Trainer, Peter J
Parkinson, Craig
Scarlett, J A
Trainer, Peter J
Citations
Altmetric:
Abstract
Epidemiological studies have highlighted the need for tight control of growth hormone (GH) and insulin-like growth factor I (IGF-I) in patients with acromegaly. Studies highlighting the events involved in GH receptor signaling have allowed the development of a pegylated GH receptor antagonist (pegvisomant) for use in humans, which has been designed to outcompete GH for the GH receptor, but which contains a position 120 amino acid substitution that prevents recruitment of a second GH receptor. This process of receptor dimerisation is crucial for signal transduction and IGF-I generation. Clinical trials of pegvisomant suggest it is the most effective treatment for acromegaly to date, as this therapy is capable of normalising serum IGF-I in up to 97% of patients when doses of 40 mg per day are used. This paper reviews the development of pegvisomant and the clinical experience in patients with acromegaly to date.
Authors
Parkinson, Craig
Scarlett, J A
Trainer, Peter J
Scarlett, J A
Trainer, Peter J
Affiliation
Department of Endocrinology, Christie Hosptial, Wilmslow Road, Manchester M20 4BX, UK.
Description
Date
2003-09-26
Publisher
Collections
Keywords
Type
Article
Citation
Pegvisomant in the treatment of acromegaly. 2003, 55 (10):1303-14 Adv. Drug Deliv. Rev.